U.S. markets closed

Cortexyme, Inc. (CRTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
56.080.00 (0.00%)
At close: 4:00PM EDT
56.01 -0.07 (-0.12%)
After hours: 05:53PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close56.08
Open56.25
Bid50.26 x 1100
Ask56.90 x 800
Day's Range53.70 - 56.60
52 Week Range26.66 - 58.99
Volume163,868
Avg. Volume225,326
Market Cap1.659B
Beta (5Y Monthly)0.75
PE Ratio (TTM)N/A
EPS (TTM)-2.81
Earnings DateAug 16, 2021 - Aug 20, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est73.86
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Hedge Funds Are Dumping Cortexyme, Inc. (CRTX)
    Insider Monkey

    Hedge Funds Are Dumping Cortexyme, Inc. (CRTX)

    Is Cortexyme, Inc. (NASDAQ:CRTX) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to work. […]

  • Cortexyme Presents Updated Baseline Data from Complete Set of Participants Enrolled in Pivotal GAIN Trial at ASCP 2021 Annual Meeting
    Business Wire

    Cortexyme Presents Updated Baseline Data from Complete Set of Participants Enrolled in Pivotal GAIN Trial at ASCP 2021 Annual Meeting

    Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with topline data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, announced the presentation of updated baseline demographic and biomarker data at the American Society of Clinical Psychopharmacology (ASCP) 2021 Annual Meeting.

  • Cortexyme to Present at Investor Conferences in June 2021
    Business Wire

    Cortexyme to Present at Investor Conferences in June 2021

    Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with topline data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, announced that Chris Lowe, the company’s chief operating officer and chief financial officer, will participate at the following virtual investor conferences in June 2021: